PMID- 31913226
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20210208
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Apr
TI  - Changes in Prostaglandin-associated Periorbital Syndrome After Switch from 
      Conventional Prostaglandin F2alpha Treatment to Omidenepag Isopropyl in 11 
      Consecutive Patients.
PG  - 326-328
LID - 10.1097/IJG.0000000000001442 [doi]
AB  - PURPOSE: We evaluated the recovery of patients with PAPS for whom the treatment 
      regimen switched from conventional prostaglandin F2alpha analogues to a new selective 
      prostaglandin-EP2 agonist: omidenepag isopropyl. PATIENTS AND METHODS: From 
      November 2018 to July 2019, we prospectively evaluated 11 patients who had been 
      using conventional PGF2alpha drugs. Digital photographs of the patients were taken 
      before the start of omidenepag isopropyl therapy and ~3 and 6 months after. Three 
      independent observers used the photographs to judged recovery according to the 5 
      signs of PAPS: deepening of the upper eyelid sulcus (DUES), flattening of the 
      lower eyelid bags, upper eyelid ptosis, ciliary hypertrichosis, and periorbital 
      skin hyperpigmentation. RESULTS: The mean age of patients was 61, and 7 patients 
      were female. The original PGF2alpha drugs were bimatoprost, latanoprost, travoprost, 
      and tafluprost. The mean duration of PGF2alpha treatment was 65 months. PAPS signs 
      were evaluated in 10 patients after 3 months and in all 11 patients after 6 
      months: After 3 and 6 months, DUES improved in 3 and 3 patients, respectively; 
      flattening of the lower eyelid bags improved in 1 and 2 patients, respectively; 
      upper eyelid ptosis did not improve in any patients; ciliary hypertrichosis 
      improved in 0 and 2 patients, respectively; and eyelid pigmentation improved in 2 
      and 8 patients, respectively. The 3 patients who showed improvement in DUES at 6 
      months had all previously used bimatoprost. CONCLUSIONS: Some PAPS signs improved 
      after patients started taking omidenepag isopropyl. Our findings will be useful 
      for patients taking antiglaucoma eye drops.
FAU - Nakakura, Shunsuke
AU  - Nakakura S
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji.
FAU - Terao, Etusko
AU  - Terao E
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji.
FAU - Fujisawa, Yasuko
AU  - Fujisawa Y
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji.
FAU - Tabuchi, Hitoshi
AU  - Tabuchi H
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji.
AD  - Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Kiuchi, Yoshiaki
AU  - Kiuchi Y
AD  - Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical 
      Sciences, Hiroshima University, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Prostaglandins F)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 1O6WQ6T7G3 (tafluprost)
RN  - 6Z5B6HVF6O (Latanoprost)
RN  - G0G0H52U6K (omidenepag isopropyl)
RN  - QXS94885MZ (Bimatoprost)
RN  - TE7660XO1C (Glycine)
RN  - WJ68R08KX9 (Travoprost)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Bimatoprost/therapeutic use
MH  - Drug Substitution
MH  - Eyelid Diseases/diagnosis/*drug therapy
MH  - Female
MH  - Glycine/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Intraocular Pressure
MH  - Latanoprost/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Orbital Diseases/diagnosis/*drug therapy
MH  - Prospective Studies
MH  - Prostaglandins F/therapeutic use
MH  - Prostaglandins F, Synthetic/*therapeutic use
MH  - Pyrazoles/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Syndrome
MH  - Travoprost/therapeutic use
EDAT- 2020/01/09 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/01/09 06:00
PHST- 2020/01/09 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/01/09 06:00 [entrez]
AID - 00061198-202004000-00014 [pii]
AID - 10.1097/IJG.0000000000001442 [doi]
PST - ppublish
SO  - J Glaucoma. 2020 Apr;29(4):326-328. doi: 10.1097/IJG.0000000000001442.